SPRY ARS Corp: מקדם חוב לטווח ארוך להון

ARS Pharmaceuticals (SPRY) specializes in creating needle-free drug delivery methods, developing a unique nasal product to combat anaphylactic shock. This daily price action for the company's shares on GURU.Markets currently stands at 7.81. However, business development is complicated by global political tensions, which disrupt raw material logistics and slow down the international approval of new medicinal products.

To assess the long-term financial stability of ARS Pharmaceuticals (SPRY), it is critical to analyze the ratio of liabilities with a maturity of over one year to equity. This ratio of long-term debt to equity determines the degree of leverage, where a low figure minimizes default risks during the technical re-equipment of bottling lines and the expansion of nasal spray production capacities.